News Focus
News Focus
Followers 27
Posts 1175
Boards Moderated 0
Alias Born 02/09/2021

Re: Timing101 post# 173502

Sunday, 04/16/2023 8:01:50 PM

Sunday, April 16, 2023 8:01:50 PM

Post# of 202269
What are they questioning? The sub was one of two formed after the merger in 2020 to hold the patent licenses. So, now they are acknowledging they are ready to start the Africa project. They don't say when it will start though. See page 11 of the 2021 Annual Disclosure and here's the link: https://www.otcmarkets.com/otcapi/company/financial-report/325767/content

Pursuant to the terms of the Business Combination Agreement, on November 24, 2020, the Company formed two new
Texas corporations as wholly-owned subsidiaries for the purpose of licensing certain patented technologies: Biogenysis,
Inc. and Virogentics, Inc.
Two Patent License Agreements
On November 30, 2020, Biogenysis, Inc., a wholly-owned subsidiary of Enzolytics, Inc., entered into a Patent License
Agreement with Bioclonetics in order to license the U.S. Provisional Patent Application No. 63/078,482, filed September 15,
2020, entitled NOVEL HIV-BINDING PEPTIDES for treating, preventing and reducing the risks of HIV, including all patents
issuing therefrom and any foreign counterparts thereof.
Also on November 30, 2020, Virogentics, Inc., a wholly-owned subsidiary of Enzolytics, Inc., entered into a Patent License
Agreement with the Zhabilov Trust in order to license the U.S. Patent No. 7,479538, entitled Irreversibly - Inactivated
pepsinogen fragment and Pharmaceutical composition the same for detecting preventing and treating HIV; U.S. Patent No.
8,066982, Irreversibly - Inactivated pepsinogen fragment and Pharmaceutical composition compressing the same for
detecting preventing and treating HIV, including all patents issuing therefrom and any foreign counterparts thereof

.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y